Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 8/20 | 0.40 |
| ▸ | MIF | P14174 | 4/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053525 | 0.85 | DGAT1 (0.42) | DRD4DGAT1CCR2KCNH2IDO1 | |
| SCHEMBL13009522 | 0.85 | DGAT1 (0.42) | DRD4DGAT1CCR2KCNH2IDO1 | |
| SCHEMBL14199021 | 0.80 | DGAT1 (0.40) | DGAT1IDO1 | |
| SCHEMBL13009528 | 0.80 | DGAT1 (0.40) | DGAT1IDO1 | |
| SCHEMBL3540783 | 0.80 | DGAT1 (0.40) | DGAT1IDO1 | |
| SCHEMBL3540778 | 0.80 | DGAT1 (0.40) | DGAT1IDO1 | |
| SCHEMBL382897 | 0.79 | ESR2 (0.56) | MIFHDAC6DGAT1 | |
| SCHEMBL382898 | 0.79 | ESR2 (0.56) | MIFHDAC6DGAT1 | |
| SCHEMBL17327330 | 0.79 | ESR2 (0.56) | MIFHDAC6DGAT1 | |
| SCHEMBL13009517 | 0.78 | KDM4E (0.38) | DGAT1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DRD4 1411/4885DEGS1 2573/4885MIF 4399/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | DRD4 1411/4885DEGS1 2573/4885MIF 4399/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DRD4 1411/4885DEGS1 2573/4885MIF 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.